And that's OK -- at least according to Oppenheimer analyst Jay Olson, who on Friday lowered his price target on CRISPR stock to $95 a share, but maintained an outperform rating on the stock. How much would you pay for a stock that might earn $25 a year in six years? CRISPR Therapeutics (CRSP 2.26%) closed last week down 8.5% after reporting first-quarter "earnings" results that looked a lot more like losses. Lacking a big milestone payment like the one in Q1 2023, CRISPR's revenue plummeted 99.5% year over ...